MedTrace Logo

Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01013142 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2015-05-13

No results posted yet for this study

Summary

The objective of this clinical study is to determine the safety of intravenous MN-221 compared to placebo when administered in subjects diagnosed with stable moderate to severe COPD.

Conditions

Interventions

DRUG

MN-221 (Dose Group 1)

i.v. infusion of MN-221 (300 mcg) or placebo over 1 hour

DRUG

MN-221 (Dose Group 2)

i.v. infusion of MN-221 (600 mcg) or placebo over 1 hour

DRUG

MN-221 (Dose Group 3)

i.v. infusion of MN-221 (1,200 mcg) or placebo over 1 hour

Sponsors & Collaborators

  • MediciNova

    lead INDUSTRY

Principal Investigators

  • Alan W Dunton, MD · MediciNova

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01013142 on ClinicalTrials.gov